GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bioject Medical Technologies Inc (OTCPK:BJCT) » Definitions » Intrinsic Value: DCF (Dividends Based)

Bioject Medical Technologies (Bioject Medical Technologies) Intrinsic Value: DCF (Dividends Based) : $ (As of May. 16, 2024)


View and export this data going back to . Start your Free Trial

What is Bioject Medical Technologies Intrinsic Value: DCF (Dividends Based)?

As of today (2024-05-16), Bioject Medical Technologies's intrinsic value calculated from the Discounted Dividend model is $.

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star) with dividend payments. If the company's Predictability Rank is 1-Star or Not Rated, or if the company does not pay dividend, the data will not be stored into our database.

Bioject Medical Technologies's Predictability Rank is Not Rated. Thus, this page is only used for demonstration purposes and the DCF related results in the screener and portfolio will appear as zero.

Margin of Safety % (DCF Dividends Based) using Discounted Dividend Model for Bioject Medical Technologies is

The historical rank and industry rank for Bioject Medical Technologies's Intrinsic Value: DCF (Dividends Based) or its related term are showing as below:

BJCT's Price-to-DCF (Dividends Based) is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.6
* Ranked among companies with meaningful Price-to-DCF (Dividends Based) only.

Bioject Medical Technologies Intrinsic Value: DCF (Dividends Based) Historical Data

The historical data trend for Bioject Medical Technologies's Intrinsic Value: DCF (Dividends Based) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioject Medical Technologies Intrinsic Value: DCF (Dividends Based) Chart

Bioject Medical Technologies Annual Data
Trend Mar01 Mar02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10
Intrinsic Value: DCF (Dividends Based)
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Bioject Medical Technologies Quarterly Data
Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11
Intrinsic Value: DCF (Dividends Based) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Bioject Medical Technologies's Intrinsic Value: DCF (Dividends Based)

For the Medical Instruments & Supplies subindustry, Bioject Medical Technologies's Price-to-DCF (Dividends Based), along with its competitors' market caps and Price-to-DCF (Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioject Medical Technologies's Price-to-DCF (Dividends Based) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bioject Medical Technologies's Price-to-DCF (Dividends Based) distribution charts can be found below:

* The bar in red indicates where Bioject Medical Technologies's Price-to-DCF (Dividends Based) falls into.



Bioject Medical Technologies Intrinsic Value: DCF (Dividends Based) Calculation

This is the intrinsic value calculated from the Discounted Dividend Model with default parameters. The calculation method is the same as Discounted Cash Flow model except adjusted dividend are used in the calculation instead of free cash flow. This is the default method of calculation with GuruFocus DCF calculator.

Usually a two-stage model is used in calculating the intrinsic value with discounted cash flow model. The first stage is called growth stage; the second is called the terminal stage. In the growth stage the company grows at a faster rate. Because it cannot grow at that rate forever, a lower rate is used for the terminal stage.

GuruFocus DDM calculator is a two-stage model. The default values are defined as:

1. Discount Rate: d = 11%
A reasonable discount rate assumption should be at least the long term average return of the stock market, which can be estimated from risk free rate plus risk premium of stock market. GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate and rounded up to the nearest integer. It is updated daily. The current risk-free rate is 4.33%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default. Then we added a risk premium of 6% to get the estimated discount rate. Some investors use their expected rate of return, which is also reasonable. A typical discount rate can be anywhere between 6% - 20%.

2. Dividend Growth Rate in the growth stage: g1 = %
The Growth Rate in the growth stage is initially set as the default 10-Year Dividend Growth Rate. In cases where the 10-year growth rate is unavailable, it defaults to using the 5-Year Dividend Growth Rate. If both the 10-year and 5-year growth rates are unavailable, the system defaults to the 3-Year Dividend Growth Rate.
However, it's important to note that there is a growth rate range. If the calculated growth rate exceeds 20%, it will be capped at 20%. Conversely, if the calculated growth rate falls below 5%, it will be adjusted to 5% to maintain a reasonable range.
=>

3. Years of Growth Stage: y1 = 10

4. Terminal Growth Rate: g2 = 4%

5. Dividends per Share: adjusted dividends per share = $.
GuruFocus uses adjusted dividends per share by default to ensure that the valuation reflects the total value of the company, as the actual dividend is only a portion of the total value.

All of the default settings can be changed in the DCF calculator and the results are calculated automatically.

Bioject Medical Technologies's Intrinsic Value: DCF (Dividends Based) for today is calculated as:

Intrinsic Value: DCF (Dividends Based)=Dividends per Share*{[(1+g1)/(1+d)+(1+g1)^2/(1+d)^2+...+(1+g1)^10/(1+d)^10]
+(1+g1)^10/(1+d)^10*[(1+g2)/(1+d)+(1+g2)^2/(1+d)^2+...+(1+g2)^10/(1+d)^10]}

set x = (1+g1)/(1+d) = (1+)/(1+0.11) =
and y = (1+g2)/(1+d) = (1+)/(1+0.11) =

Intrinsic Value: DCF (Dividends Based)=Dividends per Share*{[x+x^2+...+x^10]+x^10*[y+y^2+...+y^10]}
=Dividends per Share*[x*(1-x^10)/(1-x)+x^10*y*(1-y^10)/(1-y)]
=*
=

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based)-Current Price) /Intrinsic Value: DCF (Dividends Based)
= ( - 0.0001) /

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioject Medical Technologies  (OTCPK:BJCT) Intrinsic Value: DCF (Dividends Based) Explanation

Unlike valuation methods such as Net Current Asset Value, Tangible Book per Share, Graham Number, Median PS Value etc, discounted Dividends model evaluates the companies based on their power of future dividend distribution instead of their assets.


Be Aware

What you need to know about Discounted Dividends model:

1. The Discounted Dividends model evaluates a company based on its future dividends distribution power
2. Dividend growth is taken into account; therefore a company with a higher dividend growth rate is worth more if everything else is the same.
3. Since we are projecting future growth, it is assumed that the company will grow at the same rate as it did during the past 10 years. Therefore this model works better for the companies with consistently steady dividends distributed.
4. The Discounted Dividends model works poorly for inconsistent dividends distributor like high growth companies.
5. Your expected return from the investment is a reasonable discount rate assumption.
6. A larger margin of safety should be required for companies with less dividends distributed.

You can screen for stocks that trade below their Intrinsic Value: DCF (FCF Based) and Intrinsic Value: DCF (Earnings Based) and Intrinsic Value: DCF (Dividends Based) with the GuruFocus All-in-One Screener. Companies with a high Predictability Rank that trade at a discount to their Intrinsic Value: DCF (FCF Based) and Intrinsic Value: DCF (Earnings Based) can be found in the screen of Undervalued Predictable Companies.


Bioject Medical Technologies Intrinsic Value: DCF (Dividends Based) Related Terms

Thank you for viewing the detailed overview of Bioject Medical Technologies's Intrinsic Value: DCF (Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioject Medical Technologies (Bioject Medical Technologies) Business Description

Traded in Other Exchanges
N/A
Address
Bioject Medical Technologies Inc commenced operations in 1985 and is a developer and manufacturer of needle-free injection therapy systems (NFITS). The Companys long-term goal is to become supplier of needle-free injection systems to the pharmaceutical and biotechnology industries. It focused its business development efforts on new and existing licensing and supply agreements with pharmaceutical and biotechnology companies, as well as numerous research agreements that could guide to long-term agreements. The Companys pipeline of prospective new partnerships remains active. It is also actively pursuing additional opportunities both domestically and overseas as it expands its current product line. The Companys Biojector 2000 system (B2000) consists of two components: a hand-held, reusable jet injector and a sterile, single-use, disposable plastic syringe capable of delivering variable doses of medication up to 1.0 mL. Drug Reconstitution System - The needle-free drug reconstitution system allows for the transfer of diluents to reconstitute powdered medications into liquid form and withdrawal of liquid medication into a syringe without the use of a needle. Vitajet - The Vitajet is also composed of two components, a portable injector unit and a disposable syringe. It is smaller and lower in cost than other products in its needle-free offering. ZetaJet - The ZetaJet is Biojects latest advance in needle-free delivery systems. It consists of two components, the portable injector and an auto-disabling disposable syringe. The medical equipment market is very competitive. Bioject Medical Technologies has two patents: Biojector 2000 and Vitajet. The Companys products and manufacturing operations are subject to extensive government regulations, both in the U.S. and abroad. In the U.S., the Food and Drug Administration (FDA) administers the Federal Food, Drug and Cosmetic Act (FFDCA) and has adopted regulations to administer the FFDCA.
Executives
James C Gale director 152 W 57TH STREET, 19TH FLOOR, NEW YORK NY 10019
Sanders Morris Harris Inc/fa 10 percent owner, other: See General Remarks 600 TRAVIS, SUITE 5900, HOUSTON TX 77002
David S Tierney director C/O ABLE LABORATORIES, INC., 6 HOLLYWOOD COURT, CN 1013, SOUTH PLAINFIELD NJ 07080
Edward L Flynn director, 10 percent owner 211 SOMERVILLE ROAD RTE 202N, BEDMINISTER NJ 07921
Life Sciences Opportunities Fund Ii Lp 10 percent owner 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Lof Partners Llc other: See general remarks 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Life Sciences Opportunities Fund Instittutional Ii Lp 10 percent owner 152 W 57TH STREET 19TH FLOOR NEW YORK NY 10019
Randal D Chase director 28 GEORGIA COURT, RICHMOND HILL A6 L4E ON7
Brigid Makes director 20245 SW 95TH AVENUE, TUALATIN OR 97062
J Michael Redmond officer: Sr. VP Bus Dev. 10 CANTERBURY ROAD, WINDHAM NH 03087
Elan Corp Plc 10 percent owner TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN 2 L2 00000
Elan International Services Ltd 10 percent owner C/O TREASURY BUILDING, LOWER GRAND CANAL STREET, DUBLIN L2 2
Elan Pharmaceutical Investments Ltd 10 percent owner 102 ST JAMES COURT, FIETSS SMITH FL BERM D0 9999999999
John P Gandolfo officer: CFO 62 TERRACE ROAD, WAYNE NJ 07470
Grace K Fey director 1210 CROMWELL ROAD, HALIFAX NOVA SCOTIA A5 B3H4L2

Bioject Medical Technologies (Bioject Medical Technologies) Headlines

No Headlines